Close Menu

Galapagos

The companies will jointly validate novel drug targets identified by Scipher's molecular interaction network platform for patients with inflammatory bowel disease.

NEW YORK (GenomeWeb News) – Charles River Laboratories has signed a definitive agreement to purchase Galapagos' BioFocus and Argenta service division operations for a total consideration of €134 million ($187 million), the companies announced today.

The extension calls for the use of BioFocus' target discovery platform to deliver novel targets in support of Amgen's therapeutic programs.

BioFocus will provide Genentech with integrated medicinal chemistry, in vitro biology, and ADME services.

The two-year extension could bring in $8.6 million for Galapagos.

Following today's capital increase, the company has a share capital of more than €129 million with a total of almost 24 million shares outstanding.

Galapagos expects its drug discovery services operations to bring in around €70 million in 2010 revenues.

The new open access genomics-based small molecule database is hosted by the European Bioinformatics Institute.

The Belgian drug development and drug screening services firm has placed more than 2.1 million shares with institutional investors.

Pages

The World Bank is seeking approval for a $12 billion plan to provide low-income nations with funds to procure SARS-CoV-2 vaccines, according to Reuters.

The Washington Post reports that Herbert Tabor, who worked at the US National Institutes of Health for 77 years, has died at 101.

Science writes that public health officials and others are debating whether cycle threshold values should be included on SARS-CoV-2 results.

In Nucleic Acids Research this week: online database of SARS-CoV-2 protein structures, atlas of the human brain, and more.